Filing Analysis
Cabaletta Bio held its Annual Meeting of Stockholders on June 9, 2026, where shareholders approved a significant increase in the number of authorized shares of common stock. The company also elected two Class I directors and ratified its independent auditor.
🚩 Red Flags
- Significant increase in authorized shares (doubling from 300M to 600M) typically signals future dilution through new equity offerings.
📋 Key Facts
- Authorized shares of common stock increased from 300,000,000 to 600,000,000 (a 100% increase).
- The Certificate of Amendment became effective on June 9, 2026.
- Scott Brun, M.D. and Shawn Tomasello, MBA were elected as Class I directors for three-year terms.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (Plan Amendment Proposal) was withdrawn by the Board of Directors on May 31, 2026.
Cabaletta Bio issued a press release and updated corporate presentation providing clinical data updates for its rese-cel autoimmune portfolio. The filing highlights positive early findings in lupus, myositis, and systemic sclerosis, including progress toward registrational trials.
📋 Key Facts
- Presented data from 52 evaluable patients across myositis (17), lupus (20), and systemic sclerosis (15).
- RESET-Myositis: 80% (8/10) of DM and ASyS patients would have met the primary endpoint of the registrational cohort.
- RESET-SSc: 83% (5/6) of patients achieved rCRISS-25 and 67% (4/6) achieved rCRISS-50 at 36 weeks while off immunomodulators.
- RESET-SLE: 75% (6/8) of patients with 12 months follow-up achieved Definition of Remission in SLE (DORIS) while remaining off immunomodulators.
- Company plans to initiate a systemic sclerosis (SSc) registrational program in 4Q26.
- Topline data from the DM/ASyS registrational cohort is expected in mid-2027.
- BLA submission strategy for adult DM and JDM is planned for 2H27.
Cabaletta Bio, Inc. announced its financial results for the first quarter ended March 31, 2026, through a press release furnished to the SEC. This is a routine quarterly update on the company's financial condition and results of operations.
📋 Key Facts
- Financial results reported for the first quarter ended March 31, 2026.
- The report was filed on May 14, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results was included as Exhibit 99.1.
- The information in the report is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Cabaletta Bio reported positive early clinical data for its rese-cel therapy in a preconditioning-free cohort of pemphigus vulgaris patients and successfully demonstrated automated manufacturing using the Cellares Cell Shuttle. The data showed that 2 of 4 patients achieved drug-free clinical responses at 6 months without the need for chemotherapy preconditioning.
📋 Key Facts
- Reported clinical and translational data from 4 patients in the RESET-PV trial treated with rese-cel without preconditioning (PC-free).
- 2 of 4 patients maintained drug-free clinical responses through 24 weeks of follow-up at the lowest dose.
- Safety profile showed no dose-limiting toxicities (DLT) or ICANS, with only one patient experiencing Grade 1 cytokine release syndrome (CRS).
- First clinical use of the Cellares Cell Shuttle for automated manufacturing, with the first two doses meeting all release specifications.
- Anticipated data for higher doses of PC-free rese-cel in PV expected in 2H26; initial SLE data expected in 1H26 (June 2026).
Cabaletta Bio announced an underwritten registered direct offering of 51.7 million shares at $2.90 per share, expected to yield approximately $141 million in net proceeds. The company also provided a preliminary Q1 2026 cash balance of $117 million and updated its cash runway guidance to mid-2027.
🚩 Red Flags
- Significant equity dilution resulting from the issuance of 51.7 million new shares.
- Relatively short cash runway extension, only reaching mid-2027 despite the $141 million raise.
📋 Key Facts
- Offering of 51,725,000 shares of common stock at a price of $2.90 per share.
- Net proceeds estimated at approximately $141 million after fees.
- Preliminary cash and cash equivalents of $117 million as of March 31, 2026.
- Proceeds intended for clinical development of rese-cel, including a myositis registrational study.
- Cash runway expected to extend into mid-2027.
- Underwriters include TD Securities (USA) LLC, Guggenheim Securities, LLC, and Cantor Fitzgerald & Co.
Cabaletta Bio reported positive initial clinical data from four refractory patients in its RESET-PV trial evaluating rese-cel without preconditioning. The data showed clear biologic activity and a favorable safety profile at the lowest dose, with three of four patients remaining off immunomodulators and steroids.
📋 Key Facts
- Clinical data presented for 4 refractory patients in the RESET-PV (pemphigus vulgaris) trial.
- The trial evaluates rese-cel without the use of cyclophosphamide and fludarabine as preconditioning agents.
- 3 of 4 patients remained off all immunomodulators and steroids as of the April 2, 2026 data cut-off.
- Complete peripheral B cell elimination was observed in 3 of 4 patients.
- Safety profile: 1 patient with Grade 1 cytokine release syndrome (CRS); no ICANS observed.
- Higher dose cohorts have been enrolled with durability data anticipated in the second half of 2026.
Cabaletta Bio, Inc. has updated its corporate presentation as of April 20, 2026, and made it available on the company's website. The presentation is included as Exhibit 99.1 in this filing for public disclosure.
📋 Key Facts
- Updated corporate presentation released on April 20, 2026.
- The presentation was filed as Exhibit 99.1 under Item 8.01 (Other Events).
- The filing was signed by CEO Steven Nichtberger.
Cabaletta Bio reported its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company also released an updated corporate presentation for investors.
📋 Key Facts
- Financial results for the fiscal year ended December 31, 2025, were announced on March 23, 2026.
- An updated corporate presentation was posted to the company's website and filed as Exhibit 99.2.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).